Eliana Bignotti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eliana Bignotti has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Davide Santin
Department of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA
1 shared publication - Antonella Ravaggi
University of Brescia, Department of Clinical and Experimental Sciences, Brescia, Italy; ASST Spedali Civili of Brescia, "Angelo Nocivelli" Institute of Molecular Medicine, Brescia, Italy; ASST Spedali Civili of Brescia, Division of Obstetrics and Gynecology, Brescia, Italy
1 shared publication - Carla Donzelli
Department of Pathology, University of Brescia, Brescia, Italy
1 shared publication - Chiara Romani
Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia and ASST Spedali Civili di Brescia , Brescia
1 shared publication - Elisa Rossi
INSERM, U1144 Optimisation Thérapeutique en Neuropharmacologie (OPTeN), Faculty of Pharmacy, Université Paris-Cité, 75006 Paris, France
1 shared publication - Elisabetta Bandiera
Angelo Nocivelli" Institute of Molecular Medicine, Division of Obstetrics and Gynecology, University of Brescia, P.le Spedali Civili 1, 25123, Brescia, Italy
1 shared publication
Latest Publications
- Open Access
- 27 July 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 253
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
Traditional prognostic factors in epithelial ovarian cancer (EOC) are inadequate in predicting recurrence and long-term prognosis, but genome-wide cancer research has recently provided multiple potentially useful biomarkers. The gene codifying for Mammaglobin B (MGB-2) has been selected from our previous microarray analysis performed on 19 serous papillary epithelial ovarian cancers and its expression has been further investigated on multiple histological subtypes, both at mRNA and protein level. Since, to date, there is no information available on the prognostic significance of MGB-2 expression in cancer, the aim of this study was to determine its prognostic potential on survival in a large cohort of well-characterized EOC patients.
- 27 July 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 253
Open AccessMammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence
Traditional prognostic factors in epithelial ovarian cancer (EOC) are inadequate in predicting recurrence and long-term prognosis, but genome-wide cancer research has recently provided multiple potentially useful biomarkers. The gene codifying for Mammaglobin B (MGB-2) has been selected from our previous microarray analysis performed on 19 serous papillary epithelial ovarian cancers and its expression has been further investigated on multiple histological subtypes, both at mRNA and protein level. Since, to date, there is no information available on the prognostic significance of MGB-2 expression in cancer, the aim of this study was to determine its prognostic potential on survival in a large cohort of well-characterized EOC patients.